Notably, many of these genes (ADRA1A, BARHL2, ERAS, ESRRG, RNF220 and ST6GALNAC5) are also targets of the Polycomb Repressor Complex-2, further supporting an important role of epigenetic crosstalk in controlling rectal cancer therapeutic responsiveness. This evidence concerns the gene ADRA1A and rectal cancer.